The U.S. Food and Drug Administration has initiated a public consultation to define its regulatory strategy for medical devices powered by generative artificial intelligence. The agency published a discussion paper outlining proposed structures for risk evaluation, premarket review, and ongoing surveillance, while soliciting input from device manufacturers, healthcare providers, academic researchers, and the general public.
The move follows a rapid increase in AI applications within healthcare, where generative systems deliver advanced functionalities alongside novel risks that differ from conventional medical software. The FDA’s Digital Health Center of Excellence (DHCoE) is spearheading the initiative, framing the debate around how to maintain patient safety while encouraging technological advancement.
Acting FDA Commissioner Kyle Diamantas emphasized the transformative impact of AI on medicine and the need for U.S. leadership in shaping its safe and responsible development. “Artificial intelligence is transforming medicine, and the United States must lead in shaping how this technology is developed and used safely and responsibly,” he said. The agency’s framework aligns with its Public Health Pillar on Innovation and Global Leadership, which focuses on advancing regulatory frameworks for AI and digital health technologies.
The discussion paper introduces a two-axis framework for risk assessment to inform regulatory expectations. It also proposes a premarket evaluation approach inspired by physician training, consisting of non-clinical device benchmarking and clinical confirmation to ensure device performance before patient use. Postmarket monitoring strategies are discussed, with an emphasis on risk-proportionate oversight.
The FDA seeks input on foundation models and agentic AI systems, areas where traditional regulatory models may be insufficient. The agency aims to develop a framework that is scientifically rigorous, prioritizes patient safety, and aligns with the unique capabilities of generative AI-enabled devices. Public comments are due by October 19, 2026, and must be submitted through the Regulations.gov portal under docket FDA-2026-N-7874.
FDA Highlights Regulatory Challenges for AI-Powered Medical Tools
Generative AI in medical devices introduces unique risks compared to traditional software and AI systems, stemming from their ability to generate unpredictable outputs and adapt in novel ways. The discussion paper shows the need for regulatory approaches tailored to these complexities.
FDA leaders emphasize the consultation’s role in balancing innovation with patient safety and public trust. Input from stakeholders will shape how the FDA oversees these emerging technologies, ensuring a regulatory approach that keeps pace with rapid advancements in digital health.
